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2*, Francisco Pérez-Miralles3, Lucı́a ForeroID4,
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The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder
(NMOSD) is limited by the lack of validated disease-specific measures. The SymptoMSc-
reen (SyMS) is a patient-reported questionnaire for measuring symptom severity in different
domains affected by multiple sclerosis (MS), but has not been thoroughly evaluated in
NMOSD. The aim of this study was to assess the psychometric properties of the SyMS in a
sample of patients with NMOSD.
Methods
A non-interventional, cross-sectional study in adult subjects with NMOSD (Wingerchuk
2015 criteria) was conducted at 13 neuroimmunology clinics applying the SyMS. A non-
parametric item response theory procedure, Mokken analysis, was performed to assess the
underlying dimensional structure and scalability of items and overall questionnaire. All anal-
yses were performed with R (v4.0.3) using the mokken library.
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Results
A total of 70 patients were studied (mean age: 47.5 ± 15 years, 80% female, mean
Expanded Disability Status Scale score: 3.0 [interquartile range 1.5, 4.5]). Symptom severity
was low (median SyMS score: 19.0 [interquartile range 10.0, 32.0]). The SyMS showed a
robust internal reliability (Cronbach’s alpha: 0.90 [95% confidence interval 0.86, 0.93]) and
behaved as a unidimensional scale with all items showing scalability coefficients > 0.30. The
overall SyMS scalability was 0.45 conforming to a medium scale according to Mokken’s cri-
teria. Fatigue and body pain were the domains with the highest scalability coefficients. The
SyMS was associated with disability (rho: 0.586), and physical and psychological quality of
life (rho: 0.856 and 0.696, respectively).
Conclusions
The SyMS shows appropriate psychometric characteristics and may constitute a valuable
and easy-to-implement option to measure symptom severity in patients with NMOSD.
Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is a rare neuroinflammatory condition tar-
geting primarily the spinal cord and optic nerve and associated with severe disability [1,2].
Fatigue, pain, visual loss, and motor impairment are the most prevalent symptoms [3–5].
Depression and other psychiatric comorbid conditions are also common in NMOSD affecting
well-being and quality of life [6,7]. However, little is known about the subjective experience of
patients living with NMOSD [4,8,9]. In addition, the assessment of patients´ perspectives is
limited by the lack of validated, self-reported, NMOSD-specific measures [9].
NMOSD and multiple sclerosis (MS) are different neuroinflammatory disorders, but share
a heterogeneous spectrum of symptoms [1,7,10]. The SymptoMScreen (SyMS) is a validated,
patient-reported questionnaire for measuring symptom severity in key domains affected by
MS, and thus we hypothesized that it might be also relevant to gather the impact of NMOSD
from the patients’ perspective [11,12].
The aim of this study was to assess the psychometric properties of the SyMS questionnaire
in a sample of NMOSD patients.
Materials and methods
A non-interventional, cross-sectional study was conducted to assess the reliability, dimen-
sional structure, and item characteristics of the SyMS in patients with NMOSD (PERSPECTI-
VES-NMO study). Eligibility criteria included age at least 18 years old and a diagnosis of
NMOSD according to Wingerchuk 2015 criteria [13]. This study was conducted in accordance
with the Good Clinical Practice Guidelines of the International Conference on Harmonisation
and with the ethical principles of the Declaration of Helsinki and was approved by the investi-
gational review board of Galicia (CEIm-G), Santiago de Compostela, Spain. Patients were con-
secutively recruited in the context of their follow-up visits at thirteen hospital-based
neuroimmunology clinics between November 2019 and July 2020. All participants provided
written informed consent.
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SymptoMScreen questionnaire
The SyMS assesses symptom severity across twelve neurologic domains: mobility, hand func-
tion/dexterity, spasticity and stiffness, pain, sensory symptoms, bladder control, fatigue, vision,
dizziness, cognition, depression, and anxiety [11,12,14]. Each item is assessed on a seven-point
Likert scale: 0 (not at all affected) to 6 (total limitation). The total score ranges from 0 to 72,
with higher scores indicating more severe symptom endorsement.
This questionnaire was developed in English and has been translated into 19 languages. A
paper format is available free for download at https://www.symptomscreen.org/. The original
Spanish version of the SyMS was administered in this study only replacing the term MS by
NMOSD in the first statement: “Please circle one number that best describes how each NMOSD
symptom has affected your everyday life activities“.
Statistical analysis
We analyzed the internal reliability of the SyMS with Cronbach’s alpha index. We assessed the
underlying dimensional structure of the SyMS with a non-parametric item response theory
procedure, Mokken analysis [15]. We also used Mokken analysis to assess the scalability of
items and overall questionnaire. The scalability coefficients (Hi) for each item indicate the dis-
crimination and weight each item has on the latent variable or dimension it is purported to
measure. We required an internal reliability equal or greater than 0.70 but lower than 0.95 to
define acceptable reliability. We required scalability coefficients (Hi) for each item and the
overall scale (H), to be equal or greater than 0.30 to define an acceptable scale [15]. All analyses
were done with R (v4.0.3) using the mokken library [16,17]. Associations between the SyMS
and the Expanded Disability Status Scale (EDSS) and the 29-item Multiple Sclerosis Impact
Scale (MSIS-29) were analyzed using Spearman’s rank correlation [18,19].
Results
A total of 70 patients were studied. The mean (± SD) age was 47.5 ± 15 years and 80% were
female. The median EDSS score was 3.0 (interquartile range 1.5, 4.5). Seven patients (10%)
required a walking aid and three (4.3%) used a wheelchair. Eighteen patients (27.7%) had uni-
or bilateral visual acuity lower than 20/100. Overall symptom severity was low with a median
SyMS score of 19.0 (interquartile range 10.0, 32.0). Sociodemographic and clinical characteris-
tics of the sample are shown in Table 1.
The SyMS showed a robust internal reliability (Cronbach’s alpha 0.90 [95% confidence
interval 0.86, 0.93]) and behaved as a unidimensional scale with all items showing scalability
coefficients Hi> 0.30. The overall SyMS scalability was 0.45 conforming to a medium scale
according to Mokken’s criteria. Fatigue and body pain were the domains with the highest scal-
ability coefficients, whereas vision and bladder control were the domains with the highest lev-
els of perceived severity (Table 2 and Fig 1).
Overall SyMS score showed a significant correlation with physical and psychological MSIS-29
scores (rho = 0.856 and 0.696, p<0.0001, respectively), and EDSS score (rho = 0.586, p<0.0001).
Discussion
NMOSD is a rare autoimmune, neuroinflammatory disease with a negative impact on patients´
independence and quality of life [4,8,20]. The unpredictability trajectory of the disease makes the
experience of living with NMOSD even more difficult for patients and their caregivers [7,8,21].
The assessment of patient perspectives using standardized self-report instruments have
been inconsistently conducted in patients with neuroinflammatory and demyelinating
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disorders [9,22]. Well-designed and validated patient-oriented outcome measures in NMSOD
are needed to better capture the course of the disease and the response to treatments [3,4,9].
The US online community PatientsLikeMe developed the Neuromyelitis Optica Rating Scale
(NMORS), a self-reported, eight-item instrument to assess symptoms and disability in patients
with NMOSD [3]. The total score ranges from 0 to 100, with higher scores indicating more
severe symptom severity. Moore et al. created a 46-item patient-reported questionnaire to
assess the impact of NMOSD on life functioning and different symptom dimensions, including
vision, mobility, bladder, bowel, mood, sexual dysfunction, pain, fatigue, and cognition [9].
However, neither of the two instruments is psychometrically validated.
The SyMS is a validated, brief and easy-to-implement questionnaire to quantify symptoms
in MS [11,12]. The overall score correlates with clinical disability, physical and psychological
Table 1. Demographic and clinical characteristics.
n = 70
Age (years), mean ± SD 47.5 ± 15
Sex (female), n (%) 56 (80)
Disease duration (years), mean ± SD 9.9 ± 8.1
Anti-aquaporin-4 antibodies, n (%) 54 (77.1%)
Relapsing form, n (%) 59 (84.2)
Single-attack form, n (%) 11 (15.7)
Number of relapses since diagnosis, mean ± SD 2.9 ± 2.3
Number of relapses in the last year, mean ± SD 0.5 ± 0.9
EDSS score, median (IQR) 3.0 (1.5, 4.5)
EDSS score� 6, n (%) 10 (14.3)
SymptoMScreen score, median (IQR) 19.0 (10.0, 32.0)
Physical impact MSIS-29 score, mean ± SD 41.9 ± 16.7
Psychological impact MSIS-29 score, mean ± SD 20.9 ± 8.3
EDSS = Expanded Disability Status Scale; MSIS-29 = 29-item Multiple Sclerosis Impact Scale; IQR = interquartile
range; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0255317.t001
Table 2. Psychometric characteristics of the SymptoMScreen.
Severity levels, n (%)
Domain Hi None (score 0) Mild (score 1+2) Moderate (score 3+4) Severe (score 5+6)
Mobility 0.45 22 (31) 18 (26) 23 (33) 7 (10)
Dexterity 0.39 31 (44) 20 (29) 16 (23) 3 (4)
Spasticity 0.46 27 (39) 21 (30) 18 (26) 4 (6)
Pain 0.52 13 (19) 28 (40) 21 (30) 8 (11)
Sensory symptoms 0.49 14 (20) 28 (40) 23 (33) 5 (7)
Bladder control 0.39 21 (30) 22 (31) 17 (24) 10 (14)
Fatigue 0.53 9 (13) 29 (41) 23 (33) 9 (13)
Vision 0.36 19 (27) 27 (39) 12 (17) 12 (17)
Dizziness 0.43 36 (51) 22 (31) 8 (11) 4 (6)
Cognition 0.48 21 (30) 34 (49) 9 (13) 6 (9)
Depression 0.46 25 (36) 23 (33) 13 (19) 9 (13)
Anxiety 0.40 28 (40) 22 (31) 15 (21) 5 (7)
Hi = scalability coefficient.
https://doi.org/10.1371/journal.pone.0255317.t002
PLOS ONE Psychometric properties of the SymptoMScreen questionnaire in neuromyelitis optica spectrum disorder
PLOS ONE | https://doi.org/10.1371/journal.pone.0255317 July 29, 2021 4 / 7
health-related quality of life, and work productivity [14,23]. Green et al. assessed symptom
severity using the SyMS in a sample of 43 patients with NMOSD and 85 with MS [24].
Although overall scores were similar in both populations, vision impairment, spasticity, pain,
and bladder dysfunction were worse in patients with NMOSD compared to MS.
Our study found that the SyMS is a patient-reported instrument with a high internal reli-
ability and a unidimensional construct also in patients with NMOSD. These results enable its
implementation in clinical practice to capture the impact of the disease in multiple relevant
and clinically meaningful symptom domains. To our knowledge, this is the first study to assess
psychometric issues of the SyMS questionnaire in NMOSD, and its results help to support its
use and add to the scarce presence of patient-reported measures in NMOSD.
Less tangible symptoms, usually not detected on the standard neurological examination like
fatigue, pain or cognitive problems may be often more important to patients’ sense of well-being
and quality of life than physical disability in MS [25]. More than forty percent of 522 NMOSD
patients participating in a recent survey reported moderate or severe disability due to fatigue and
pain [3]. Cognitive impairment in NMOSD may already affect patients with a low level of physi-
cal disability [26]. A meta-analysis including 25 studies and 761 patients found a prevalence of
cognitive impairment of 34% (95% CI:31–37%) [27]. Longer disease duration, fatigue, pain, and
sleep disturbances were associated with cognitive impairment [26]. These “less overt impair-
ments” stress the need for including patient-centered measures in clinical practice.
Our study population included a sample of clinically stable NMOSD patients with a
medium degree of physical disability and mostly with positive anti-aquaporin-4 antibodies.
The fact that most of the recruitment period coincided with the onset of the COVID-19 pan-
demic could influence the selection of patients with this profile, since the most disabled
patients avoided conducting face-to-face consultations. The results may thus not be generaliz-
able to subjects with less stable disease status or higher disability and other serologic subtypes.
The small sample size due to a low prevalence of NMOSD did not allow us to perform a
parametric confirmatory factor analysis and compare the fit of different solutions to data [28].
Further studies with a larger sample size are needed to confirm the unidimensional structure
of the SyMS. Despite this limitation, the sample of 70 subjects was managed at 13 different
clinics on a national level, representing NMOSD patients across the country.
Conclusion
Although the SyMS is not a disease-specific measurement, it shows appropriate psychometric
characteristics and may constitute a brief and reliable option to assess symptom severity in
patients with NMOSD.
Fig 1. Symptom severity.
https://doi.org/10.1371/journal.pone.0255317.g001
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